Knowledge Ecology International Europe

Tweet this page
<
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 06 Jan 2021
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

37,500€

Financial year: Jan 2019 - Dec 2019

Lobbyists (Full time equivalent)

0.5 Fte (1)

Lobbyists with EP accreditation

0

High-level Commission meetings

1

Lobbying Costs over the years

  • Info

    Knowledge Ecology International Europe   (KEI Europe)

    EU Transparency Register

    274093330410-67 First registered on 26 Feb 2018

    Goals / Remit

    Knowledge Ecology International Europe (KEI Europe) is a non-profit organization focusing on the management of knowledge, including innovation and access to knowledge goods.

    KEI Europe is a not-for-profit Swiss association with offices in Geneva, Switzerland.

    KEI Europe monitors Brussels and Geneva-based trade, health and IPR negotiations, KEI Europe has extensive contacts within governments, academics, consumers organizations and other stakeholders.

    As part of its work, KEI Europe endeavors to ensure policy coherence across between positions adopted by the European Union in Brussels with their engagement with global institutions, such as the WHO, WIPO and WTO

    Main EU files targeted

    http://keieurope.org/actions.html

    On 14 August 2020, KEI Europe submitted comments on the Intellectual Property Action Plan
    On 7 July 2020, KEI Europe submitted comments on the pharmaceutical strategy roadmap.
    On 3 March 2020, KEI Europe submitted comments on the cancer roadmap.


    In recent years, KEI Europe has advanced a positive agenda in the Transatlantic Trade and Investment (TTIP) negotiations, submitted a detailed proposal to the Government of the United Kingdom requesting the government to issue a compulsory licence on the costly breast cancer treatment, T-DM1, and engaged in media advocacy with the Franco-German television network, ARTE, on the subject of donor capture of the World Health Organization (WHO).


    Horizon 2020


    2 February 2017. KEI Europe, along with a coalition of groups, called upon the European Commission to reframe Horizon 2020 to explore alternative models of innovation that delinked the cost of R&D from the price of medicines.

    January 2017. The joint submission to the Horizon 2020 consultation established six key recommendations that the European Commission should consider during their review process, including increased public investment in biomedical R&D funding, mandates on open data, and increased transparency.

    Transatlantic Trade and Investment Partnership Agreement

    24 February 2016. KEI Europe delivered an intervention before EU and US TTIP negotiators as well as stakeholders during the 12th round of negotiations in Brussels.

    15 July 2015. KEI Europe presented an intervention on issues related to intellectual property and public health at the TTIP stakeholder event during the negotiations in Brussels.

    13 July 2014. KEI Europe Submission: European Commission's Public consultation on modalities for investment protection and ISDS in TTIP.

    Address

    Head Office
    Route de Morillons 1
    Geneva 1211
    SWITZERLAND
  • People

    Total lobbyists declared

    1

    Employment timeLobbyists
    50%1

    Lobbyists (Full time equivalent)

    0.5

    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    III - Non-governmental organisations

    Subcategory

    Non-governmental organisations, platforms and networks and similar

  • Networking

    Affiliation

    Trans Atlantic Consumer Dialogue - http://tacd.org/

    Member organisations

    None declared

  • Financial Data

    Closed financial year

    Jan 2019 - Dec 2019

    Lobbying costs for closed financial year

    37,500€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Communication activities

    http://keieurope.org/actions.html
    http://keieurope.org/press/

    Some highlights include:

    WHO transparency resolution



    On 6 March 2019, 83 civil society organizations (including KEI Europe) and 20 individuals wrote an open letter to WHO member states requesting support for Italy’s resolution on “Improving the transparency of markets for drugs, vaccines and other health-related technologies”. The text of the transparency resolution can be found here. Currently, Greece, Malaysia, and Slovenia are co-sponsors of the Italian transparency resolution.

    Third Country Report on the protection and enforcement of intellectual property rights in third countries

    On 16 April 2018, KEI Europe and 32 groups wrote a letter to the European Commission’s Trade Commissioner, Cecilia Malmström, expressing concerns over the Commission’s
    Third Country Report on the protection and enforcement of intellectual property rights in third countries and plans to create an EU Watch List. The text of the letter can be found here: http://keieurope.org/wp-content/uploads/2018/04/Open-Letter-to-Commissioner-Malmström_-EU-Watch-List-2.pdf

    The Commission response can be found here: http://keieurope.org/2018/05/17/the-european-commission-response-to-civil-society-concerns-over-the-third-country-report-on-the-protection-of-iprs/

    Romania: Hepatitis C (HCV)

    KEI Europe has advanced its efforts on compulsory licensing of medical technologies in order to increase access to several drugs in a variety of markets globally. KEI has taken active steps towards increasing access to new, highly effective hepatitis C virus (HCV) treatments in Europe, beginning with Romania. KEI Europe’s endeavors in Romania in relation to the compulsory licensing of HCV treatments was featured in a Politico Europe article published on 16 March 2016 (Skyhigh drug prices made Romania mull unusual path, http://www.politico.eu/pro/high-drug-prices-romania-changes-patents-hepatitis).


    United Kingdom: T-DM1

    Between 2016 and 2017, KEI Europe spearheaded the Coalition for Affordable T-DM1’s campaign in the United Kingdom of Great Britain and Northern Ireland (UK) requesting the UK government to authorize the domestic manufacture and/or importation, use and sale of biosimilar versions of trastuzumab emtansine (T-DM1) used in the treatment of breast cancer, to be supplied to the government for use and sale in the UK. This followed on from the Coalition for Affordable T-DM1’s October 2015 notice of intent requesting for the government to exercise Crown Use provisions on the patents on T-DM1. To see the October 2015 notice of intent in full, please see: (http://keieurope.org/files/JeremyHuntIntenttoRequest1October2015.pdf). To see the full detailed submission, see: http://keieurope.org/files/JeremyHunt25November2016CompulsoryLicenceRequest.pdf

    World Health Organization

    30 March 2017. KEI Europe, in conjunction with sixteen other civil society groups, submitted a letter to the EU urging they voice support for a resolution on a feasibility study concerning delinkage models for cancer treatment R&D at the upcoming 70th World Health Assembly.

    WTO Agreement on the Supply of Public Goods

    27-29 March 2015. KEI Europe convened an expert meeting to consider a text for a World Trade Organization (WTO) Agreement for the Supply of Social/Public Goods (SGA Agreement). The meeting was held in Berlin, Germany and served as a space for experts with backgrounds in international trade, law, the environment, development, public health and open collaborative development models to review draft articles of the proposed agreement on social goods and provide technical and strategic advice. The report of the meeting can be found here:

    https://www.boell.de/sites/default/files/final_report_wtoagreementpublicgoods.pdf

    Other activities

    None declared

  • Meetings

    Meetings

    1 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

Download this datacard